StemCell Therapy

Denali Therapeutics Inc (DNLI) is near the top in its industry group according to InvestorsObserver. DNLI gets an overall rating of 65. That means it scores higher than 65 percent of stocks. Denali Therapeutics Inc gets a 84 rank in the Biotechnology industry. Biotechnology is number 31 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 65 means the stock is more attractive than 65 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Denali Therapeutics Inc (DNLI) stock is trading at $36.01 as of 3:36 PM on Monday, Sep 14, a rise of $4.02, or 12.57% from the previous closing price of $31.99. The stock has traded between $31.75 and $36.12 so far today. Volume today is high. So far 1,773,161 shares have traded compared to average volume of 842,601 shares.

Click Here to get the full Stock Score Report on Denali Therapeutics Inc (DNLI) Stock.

Link:
Is Denali Therapeutics Inc (DNLI) a Winner in the Biotechnology Industry? - InvestorsObserver

The 63 rating InvestorsObserver gives to Turning Point Therapeutics Inc (TPTX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 81 percent of stocks in the Biotechnology industry, TPTXs 63 overall rating means the stock scores better than 63 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Turning Point Therapeutics Inc (TPTX) stock is trading at $80.68 as of 2:39 PM on Monday, Sep 14, an increase of $9.58, or 13.47% from the previous closing price of $71.10. The stock has traded between $72.52 and $80.68 so far today. Volume today is 269,852 compared to average volume of 295,953.

Click Here to get the full Stock Score Report on Turning Point Therapeutics Inc (TPTX) Stock.

Read more from the original source:
Is Turning Point Therapeutics Inc (TPTX) a Winner in the Biotechnology Industry? - InvestorsObserver

The 47 rating InvestorsObserver gives to Cara Therapeutics Inc (CARA) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 50 percent of stocks in the Biotechnology industry, CARAs 47 overall rating means the stock scores better than 47 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Cara Therapeutics Inc (CARA) stock is trading at $15.48 as of 1:09 PM on Monday, Sep 14, an increase of $0.57, or 3.82% from the previous closing price of $14.91. The stock has traded between $14.96 and $15.48 so far today. Volume today is 308,112 compared to average volume of 341,120.

Click Here to get the full Stock Score Report on Cara Therapeutics Inc (CARA) Stock.

View post:
Is Cara Therapeutics Inc (CARA) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The 51 rating InvestorsObserver gives to AIM ImmunoTech Inc (AIM) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 57 percent of stocks in the Biotechnology industry, AIMs 51 overall rating means the stock scores better than 51 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 51 would rank higher than 51 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

AIM ImmunoTech Inc (AIM) stock is trading at $1.80 as of 10:03 AM on Monday, Sep 14, a gain of $0.03, or 1.69% from the previous closing price of $1.77. The stock has traded between $1.78 and $1.84 so far today. Volume today is less active than usual. So far 108,630 shares have traded compared to average volume of 3,605,488 shares.

Click Here to get the full Stock Score Report on AIM ImmunoTech Inc (AIM) Stock.

See the article here:
Is AIM ImmunoTech Inc (AIM) The Right Choice in Biotechnology? - InvestorsObserver

A rating of 28 puts Clovis Oncology Inc (CLVS) near the bottom of the Biotechnology industry according to InvestorsObserver. Clovis Oncology Inc's score of 28 means it scores higher than 28% of stocks in the industry. Clovis Oncology Inc also received an overall rating of 36, putting it above 36% of all stocks. Biotechnology is ranked 31 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Clovis Oncology Inc (CLVS) stock is trading at $6.68 as of 10:47 AM on Monday, Sep 14, a rise of $0.64, or 10.52% from the previous closing price of $6.04. The stock has traded between $6.26 and $6.85 so far today. Volume today is below average. So far 3,761,442 shares have traded compared to average volume of 5,153,337 shares.

Click Here to get the full Stock Score Report on Clovis Oncology Inc (CLVS) Stock.

Read this article:
Should You Buy Clovis Oncology Inc (CLVS) in Biotechnology Industry? - InvestorsObserver

Axsome Therapeutics Inc (AXSM) is near the top in its industry group according to InvestorsObserver. AXSM gets an overall rating of 62. That means it scores higher than 62 percent of stocks. Axsome Therapeutics Inc gets a 80 rank in the Biotechnology industry. Biotechnology is number 31 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Axsome Therapeutics Inc (AXSM) stock is trading at $82.28 as of 10:59 AM on Monday, Sep 14, an increase of $9.25, or 12.67% from the previous closing price of $73.03. The stock has traded between $74.40 and $82.40 so far today. Volume today is 290,235 compared to average volume of 369,883.

Click Here to get the full Stock Score Report on Axsome Therapeutics Inc (AXSM) Stock.

See the rest here:
Is Axsome Therapeutics Inc (AXSM) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Global Blood Cell Analyzer Market to Reach $2. 1 Billion by 2027. Amid the COVID-19 crisis, the global market for Blood Cell Analyzer estimated at US$1. 5 Billion in the year 2020, is projected to reach a revised size of US$2.

New York, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Blood Cell Analyzer Industry" - https://www.reportlinker.com/p05960820/?utm_source=GNW 1 Billion by 2027, growing at aCAGR of 4.8% over the period 2020-2027. Semi-automated Biochemistry Analyzers, one of the segments analyzed in the report, is projected to record 4.5% CAGR and reach US$539.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Fully Automated Biochemistry Analyzers segment is readjusted to a revised 4.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $439.7 Million, While China is Forecast to Grow at 4.5% CAGR

The Blood Cell Analyzer market in the U.S. is estimated at US$439.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$366.3 Million by the year 2027 trailing a CAGR of 4.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 3.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.We bring years of research experience to this 8th edition of our report. The 277-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05960820/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Global Competitor Market Shares Blood Cell Analyzer Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Blood Cell Analyzer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 2: World Historic Review for Blood Cell Analyzer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 3: World 15-Year Perspective for Blood Cell Analyzer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Semi-automated Biochemistry Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 5: World Historic Review for Semi-automated Biochemistry Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 6: World 15-Year Perspective for Semi-automated Biochemistry Analyzers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Fully Automated Biochemistry Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 8: World Historic Review for Fully Automated Biochemistry Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 9: World 15-Year Perspective for Fully Automated Biochemistry Analyzers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Bench-top by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 11: World Historic Review for Bench-top by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 12: World 15-Year Perspective for Bench-top by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Floor-standing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 14: World Historic Review for Floor-standing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 15: World 15-Year Perspective for Floor-standing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 17: World Historic Review for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 18: World 15-Year Perspective for Clinical Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Drug development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 20: World Historic Review for Drug development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 21: World 15-Year Perspective for Drug development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 26: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 27: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 29: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 30: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 32: World Historic Review for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 33: World 15-Year Perspective for Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 35: World Historic Review for Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 36: World 15-Year Perspective for Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 38: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 39: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 40: World Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 41: World Historic Review for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 42: World 15-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES Market Facts & Figures US Blood Cell Analyzer Market Share (in %) by Company: 2019 & 2025 Market Analytics Table 43: USA Current & Future Analysis for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 44: USA Historic Review for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 45: USA 15-Year Perspective for Blood Cell Analyzer by Product Type - Percentage Breakdown of Value Sales for Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers for the Years 2012, 2020 & 2027

Table 46: USA Current & Future Analysis for Blood Cell Analyzer by Modality - Bench-top and Floor-standing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 47: USA Historic Review for Blood Cell Analyzer by Modality - Bench-top and Floor-standing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 48: USA 15-Year Perspective for Blood Cell Analyzer by Modality - Percentage Breakdown of Value Sales for Bench-top and Floor-standing for the Years 2012, 2020 & 2027

Table 49: USA Current & Future Analysis for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 50: USA Historic Review for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 51: USA 15-Year Perspective for Blood Cell Analyzer by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug development and Other Applications for the Years 2012, 2020 & 2027

Table 52: USA Current & Future Analysis for Blood Cell Analyzer by End-Use - Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 53: USA Historic Review for Blood Cell Analyzer by End-Use - Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 54: USA 15-Year Perspective for Blood Cell Analyzer by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2020 & 2027

CANADA Table 55: Canada Current & Future Analysis for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 56: Canada Historic Review for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 57: Canada 15-Year Perspective for Blood Cell Analyzer by Product Type - Percentage Breakdown of Value Sales for Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers for the Years 2012, 2020 & 2027

Table 58: Canada Current & Future Analysis for Blood Cell Analyzer by Modality - Bench-top and Floor-standing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 59: Canada Historic Review for Blood Cell Analyzer by Modality - Bench-top and Floor-standing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 60: Canada 15-Year Perspective for Blood Cell Analyzer by Modality - Percentage Breakdown of Value Sales for Bench-top and Floor-standing for the Years 2012, 2020 & 2027

Table 61: Canada Current & Future Analysis for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 62: Canada Historic Review for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 63: Canada 15-Year Perspective for Blood Cell Analyzer by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug development and Other Applications for the Years 2012, 2020 & 2027

Table 64: Canada Current & Future Analysis for Blood Cell Analyzer by End-Use - Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 65: Canada Historic Review for Blood Cell Analyzer by End-Use - Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 66: Canada 15-Year Perspective for Blood Cell Analyzer by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2020 & 2027

JAPAN Table 67: Japan Current & Future Analysis for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 68: Japan Historic Review for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 69: Japan 15-Year Perspective for Blood Cell Analyzer by Product Type - Percentage Breakdown of Value Sales for Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers for the Years 2012, 2020 & 2027

Table 70: Japan Current & Future Analysis for Blood Cell Analyzer by Modality - Bench-top and Floor-standing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 71: Japan Historic Review for Blood Cell Analyzer by Modality - Bench-top and Floor-standing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 72: Japan 15-Year Perspective for Blood Cell Analyzer by Modality - Percentage Breakdown of Value Sales for Bench-top and Floor-standing for the Years 2012, 2020 & 2027

Table 73: Japan Current & Future Analysis for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 74: Japan Historic Review for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 75: Japan 15-Year Perspective for Blood Cell Analyzer by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug development and Other Applications for the Years 2012, 2020 & 2027

Table 76: Japan Current & Future Analysis for Blood Cell Analyzer by End-Use - Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 77: Japan Historic Review for Blood Cell Analyzer by End-Use - Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 78: Japan 15-Year Perspective for Blood Cell Analyzer by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2020 & 2027

CHINA Table 79: China Current & Future Analysis for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 80: China Historic Review for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 81: China 15-Year Perspective for Blood Cell Analyzer by Product Type - Percentage Breakdown of Value Sales for Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers for the Years 2012, 2020 & 2027

Table 82: China Current & Future Analysis for Blood Cell Analyzer by Modality - Bench-top and Floor-standing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 83: China Historic Review for Blood Cell Analyzer by Modality - Bench-top and Floor-standing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 84: China 15-Year Perspective for Blood Cell Analyzer by Modality - Percentage Breakdown of Value Sales for Bench-top and Floor-standing for the Years 2012, 2020 & 2027

Table 85: China Current & Future Analysis for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 86: China Historic Review for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 87: China 15-Year Perspective for Blood Cell Analyzer by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug development and Other Applications for the Years 2012, 2020 & 2027

See the original post here:
Global Blood Cell Analyzer Industry - Yahoo Finance

NEWARK, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today announced the appointment of Rain co-founder Robert Doebele, MD, PhD, as chief scientific officer (CSO). Dr. Doebele has served as chair of the scientific advisory board and acting CSO since Rains founding. He will now transition to Rain full-time in the executive vice president (EVP) and CSO role, departing his position at the University of Colorado, Denver as associate professor of medicine. In his new role, Dr. Doebele will be responsible for leading Rains research and development efforts.

While at the University of Colorado, Dr. Doebele discovered NTRK1 fusions in lung cancer and pioneered the development of the pan-TRK inhibitor ARRY-470, subsequently renamed larotrectinib (VITRAKVI) from Loxo Oncology, and entrectinib (ROZLYTREK) from Ignyta Pharmaceuticals.

Working with Bob since the founding of Rain has been a great privilege, and we are thrilled to officially welcome him in a full-time capacity, said Avanish Vellanki, co-founder and chief executive officer of Rain. As a visionary leader in the precision oncology space with unparalleled experience in developing tumor-agnostic approaches to cancer treatment, we are in keen anticipation of Bobs impact on the corporate biotechnology industry post his departure from academia.

Dr. Doebele added, Rain is at a pivotal juncture in its evolution, and I am excited to transition full time to the company. Rains pipeline, which now includes RAIN-32, a potent MDM2 inhibitor, and a RAD52 inhibitor program in addition to our first clinical candidate, Tarlox, has the potential to make a transformative impact in the lives of patients with difficult-to-treat cancers. I look forward to leading the team as we develop tumor-agnostic, biomarker-driven trials to advance our targeted oncology candidates.

Dr. Doebele co-founded Rain Therapeutics in April 2017 and currently serves as chair of the scientific advisory board. Prior to joining Rain full time, Dr. Doebele served as associate professor of medicine in the division of medical oncology at the University of Colorado School of Medicine, director of the Thoracic Oncology Research Initiative at the University of Colorado Cancer Center and as principle investigator for the University of Colorado Lung Cancer Specialized Program of Research Excellence. In addition, he served as a senior editor of the AACR journal, Clinical Cancer Research and was elected to the American Society for Clinical Investigation in 2018. Dr. Doebele received his AB in molecular biology from Princeton University and received his MD and PhD in immunology from the University of Pennsylvania. He conducted his internal medicine residency and medical oncology fellowship at the University of Chicago.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing targeted therapies for patients with cancer. Rains lead program is RAIN-32, a small molecule MDM2 inhibitor for patients with well-differentiated and de-differentiated liposarcoma, and other indications exhibiting MDM2 gene amplification or overexpression. RAIN-32 has completed clinical trials in certain solid tumors and hematological malignancies and has received FDA Orphan Drug Designation for patients with liposarcoma. Tarloxotinib, a hypoxia-activated pan-HER inhibitor is in clinical trials for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations and HER2 activating mutations, as well as a tumor-agnostic cohort for patients with NRG1, EGFR, HER2, and HER4 fusions. Rain is also developing a potential first-in-class inhibitor of RAD52 in the DNA Damage Response (DDR) pathway as a synthetic lethal strategy for tumors with BRCA1/2 mutations. For more information, visit http://www.rainthera.com.

Media Contact for Rain

Cait Williamson, PhDLifeSci Communications+1.646.751.4366cait@lifescicomms.com

See the article here:
Rain Therapeutics Announces Appointment of Robert Doebele, MD, PhD as Executive Vice President and Chief Scientific Officer - GlobeNewswire

FLORHAM PARK, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotech or the Company) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that Frank Bedu-Addo, CEO of PDS Biotech, will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 16th and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23rd.

H.C. Wainwright & Co. 22nd Annual Global Investment Conference:Date: Wednesday, September 16th, 2020Location: https://wsw.com/webcast/hcw7/pdsb/1599649Time: 2:30 PM ET

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit:Date: Wednesday, September 23rd, 2020Location: https://wsw.com/webcast/oppenheimer5/pdsb/2703033Time: 4:10 PM ET

A replay of the Oppenheimer presentation will be available on the Companys website for 90 days following the event. Investors attending the conferences virtually who are interested in meeting with Company management should contact their H.C. Wainwright & Co. and Oppenheimer representatives.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and include statements regarding the proposed public offering and anticipated closing. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including market conditions, whether the proposed offering is completed, the satisfaction of customary closing conditions related to the proposed offering and the other factors described in PDS Biotechs filings with the SEC. The information in this release is provided only as of the date of this release, and PDS Biotech undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechnologyPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

James SaliernoThe Ruth GroupPhone: +1 (646) 536-7028 / +1 (973) 255-8361Email: jsalierno@theruthgroup.com

Link:
PDS Biotechnology to Participate in Upcoming Healthcare Investor Conferences - GlobeNewswire

Flow cytometry marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 7.51 billion by 2027 growing at a CAGR of 8.56% in the above-mentioned forecast period.

Flow Cytometry market analysis gives clear idea on various segments that are relied upon to observe the quickest business development amid the estimate forecast frame. This Flow Cytometry report indicates a professional and all-inclusive study of the market which focuses on primary and secondary drivers, market share, competitor analysis, leading segments and geographical analysis. With the particular base year and the historic year, definite estimations and calculations are carried out in this report. The Flow Cytometry market research report displays a comprehensive study on production capacity, consumption, import and export for all the major regions across the globe.

Access Sample Copy of Research Report:https://databridgemarketresearch.com/request-a-sample/?dbmr=global-flow-cytometry-market

Some of the major players operating in this market are Bio-Rad Laboratories, Inc., Miltenyi Biotec Sysmex Partec GmbH, BIOMRIEUX, Mechatronics,, Apogee Flow Systems Ltd., Stratedigm, Inc., Sony Biotechnology Inc., BD., Thermo Fisher Scientific Inc., Merck KGaA, ACEA BIO, Agilent Technologies , Luminex Corporation. , Enzo Life Sciences, Inc., Beckman Coulter, Inc., Takara Bio Inc. among others.

North America dominates the flow cytometry market due to presence of supportive government reforms for the development of advanced technologies for molecular diagnostics, presence of a large number of clinical research labs and major pharmaceuticals in the U.S., while Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2020 to 2027 due to supportive government funding for the biotech industry development and presence of untapped opportunities, constantly improving healthcare infrastructure, rapid economic development, and rising patient awareness levels.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Flow cytometry market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for flow cytometry market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the flow cytometry market. The data is available for historic period 2010 to 2018.

Register Now @https://www.databridgemarketresearch.com/digital-conference/conference-on-rare-disease-and-orphan-drugs/group-delegate-registration

Global Flow Cytometry Market Drivers & Restraints:

The growing public-private initiatives in the field of immunology andimmuno-oncologyresearch will help in driving the growth of the flow cytometry market.

Increasing incidence and prevalence of HIV/AIDS and cancer, availability of application-specific products, growing adoption offlow cytometrytechniques in research and academia, increasing incorporation of AI platforms in flow cytometry workflows and advancements in flow cytometry software along with technological advancement will likely to accelerate the growth of the flow cytometry market in the forecast period of 2020-2027.

On the other hand, evolving pipeline for stem cell research and adoption of recombinant DNA technology forantibodyproduction will further boost various opportunities that will lead to the growth of the flow cytometry market in the above mentioned forecast period.

Limited purchasing power of end users and significant product costs will likely to hamper the growth of the flow cytometry market in the above mentioned forecast period.

Segmentation:Global Flow Cytometry Market

By Technology

(cell-based flow cytometry, bead-based flow cytometry),

Products

(Reagents And Consumables, Flow Cytometry Instruments, Accessories, Services),

Application

(Research Applications, Clinical Application, Industrial Applications),

End User

(Academic & Research Institutes Pharmaceutical & Biotechnology Companies, Hospitals, Clinical Testing Laboratories, Blood Bank, Others),

Geography

(North America, Europe, Asia-Pacific, South America, Middle East & Africa)

Any inquiry, Speak to Our Expert:https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-flow-cytometry-market

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:Sopan.gedam@databridgemarketresearch.com

Original post:
Global Flow Cytometry Market Current Trends And Efficient Techniques, Forecast 2027|Stratedigm, Inc., Sony Biotechnology Inc., BD., Thermo Fisher...

When close to half the companies in Taiwan have price-to-earnings ratios (or P/Es) below 18x, you may consider Universal Vision Biotechnology Co., Ltd. (GTSM:3218) as a stock to avoid entirely with its 65.8x P/E ratio. However, the P/E might be quite high for a reason and it requires further investigation to determine if its justified.

With earnings growth thats superior to most other companies of late, Universal Vision Biotechnology has been doing relatively well. The P/E is probably high because investors think this strong earnings performance will continue. If not, then existing shareholders might be a little nervous about the viability of the share price.

See our latest analysis for Universal Vision Biotechnology

Theres an inherent assumption that a company should far outperform the market for P/E ratios like Universal Vision Biotechnologys to be considered reasonable.

Retrospectively, the last year delivered an exceptional 51% gain to the companys bottom line. Pleasingly, EPS has also lifted 183% in aggregate from three years ago, thanks to the last 12 months of growth. Accordingly, shareholders would have probably welcomed those medium-term rates of earnings growth.

Shifting to the future, estimates from the two analysts covering the company suggest earnings should grow by 44% per annum over the next three years. With the market only predicted to deliver 8.8% per annum, the company is positioned for a stronger earnings result.

With this information, we can see why Universal Vision Biotechnology is trading at such a high P/E compared to the market. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.

While the price-to-earnings ratio shouldnt be the defining factor in whether you buy a stock or not, its quite a capable barometer of earnings expectations.

As we suspected, our examination of Universal Vision Biotechnologys analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. Right now shareholders are comfortable with the P/E as they are quite confident future earnings arent under threat. Unless these conditions change, they will continue to provide strong support to the share price.

You should always think about risks. Case in point, weve spotted 1 warning sign for Universal Vision Biotechnology you should be aware of.

Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with a strong growth track record, trading on a P/E below 20x.

PromotedIf youre looking to trade Universal Vision Biotechnology, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Go here to read the rest:
Market Participants Recognise Universal Vision Biotechnology Co., Ltd.s (GTSM:3218) Earnings - Simply Wall St

This report presents the worldwide Food Biotechnology market size (value, production and consumption), splits the breakdown (data status 2019 and forecast to 2025), by manufacturers, region, type and application.

This study also analyzes the Food Biotechnology market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the Food Biotechnology market.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2759103&source=atm

The report provides a valuable source of insightful data for business strategists and competitive analysis of Food Biotechnology market. It provides the Food Biotechnology industry overview with growth analysis and futuristic cost, revenue and many other aspects. The research analysts provide an elaborate description of the value chain and its distributor analysis. This extensive Food Biotechnology study provides comprehensive data which enhances the understanding, scope and application of this report.

segment by Type, the product can be split intoTransgenic CropsSynthetic Biology Derived ProductsMarket segment by Application, split intoAnimalsPlantsOther

Market segment by Regions/Countries, this report coversNorthAmericaEuropeChinaJapanSoutheastAsiaIndiaCentral & South America

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2759103&source=atm

Regional Analysis for Food Biotechnology Market:

For comprehensive understanding of market dynamics, the global Food Biotechnology market is analyzed across key geographies namely: United States, China, Europe, Japan, and Rest of the World (South-east Asia, India, and others). Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding.

Influence of the Food Biotechnology market report:

-Comprehensive assessment of all opportunities and risk in the Food Biotechnology market.

Food Biotechnology market recent innovations and major events.

-Detailed study of business strategies for growth of the Food Biotechnology market-leading players.

-Conclusive study about the growth plot of Food Biotechnology market for forthcoming years.

-In-depth understanding of Food Biotechnology market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Food Biotechnology market.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2759103&licType=S&source=atm

The report has 150 tables and figures browse the report description and TOC:

Table of Contents

1 Study Coverage

1.1 Food Biotechnology Product

1.2 Key Market Segments in This Study

1.3 Key Manufacturers Covered

1.4 Market by Type

1.4.1 Global Food Biotechnology Market Size Growth Rate by Type

1.5 Market by Application

1.5.1 Global Food Biotechnology Market Size Growth Rate by Application

2 Executive Summary

2.1 Global Food Biotechnology Market Size

2.1.1 Global Food Biotechnology Revenue 2014-2025

2.1.2 Global Food Biotechnology Production 2014-2025

2.2 Food Biotechnology Growth Rate (CAGR) 2019-2025

2.3 Analysis of Competitive Landscape

2.3.1 Manufacturers Market Concentration Ratio

2.3.2 Key Food Biotechnology Manufacturers

2.3.2.1 Food Biotechnology Manufacturing Base Distribution, Headquarters

2.3.2.2 Manufacturers Food Biotechnology Product Offered

2.3.2.3 Date of Manufacturers in Food Biotechnology Market

2.4 Key Trends for Food Biotechnology Markets & Products

3 Market Size by Manufacturers

3.1 Food Biotechnology Production by Manufacturers

3.1.1 Food Biotechnology Production by Manufacturers

3.1.2 Food Biotechnology Production Market Share by Manufacturers

3.2 Food Biotechnology Revenue by Manufacturers

3.2.1 Food Biotechnology Revenue by Manufacturers (2019-2025)

3.2.2 Food Biotechnology Revenue Share by Manufacturers (2019-2025)

3.3 Food Biotechnology Price by Manufacturers

3.4 Mergers & Acquisitions, Expansion Plans

More Information.

View original post here:
Food Biotechnology Market : The report gives immense knowledge on the competitive nature of key players - Daily Research Chronicle

Report Highlights

Several significant developments have aided and accelerated the growth of markets in biotechnology, in the period of review. Notable recent advancements in biotechnology are CRISPR, Spheroids for drug development, Quantitative Cell Based Assay using high content analysis platform and Luciferase based high-throughput screening assay. Such technologies assure the wide adoption of cell line technologies for drug development, simplify the gene editing process making it cost-effective.

Companies operating in cell line market are investing huge amount in setting up manufacturing units with advanced state of art facility and expanded production facilities. At the same time, the genetic sequencing technology is advancing at a great pace especially in the healthcare sector in diagnosis of various cancers.

Gene therapy technology has opened new avenues which places emphasis on curing disease that do not have an effective therapeutic availability. Johnson & Johnson, together with the University of Pennsylvania, is developing a third-generation AAV-based gene therapy for Alzheimers disease. The goal is to use AAV viral delivery to initiate the expression of therapeutic anti-Alzheimers antibodies in the brain. Novartis launched Zolgensma for the treatment of spinal muscular atrophy. The research represents a novel way to get biologics into the brain to treat Alzheimers disease and other neurological diseases. This is expected to pave way for further innovations in AAV-based gene therapy.

The sector continuously faces some challenges related to marketing, paying for innovation, pricing pressures from the government organizations.

Paying for development costs is always most critical part for the manufacturers. In 2019, gene therapies and many cell biology technologies are developed to address the needs of some important diseases and proven to be effective. However, this comes for a high cost. For example, Zolgensma, a viral vector based gene therapy for the treatment of spinal muscular atrophy costs around $5 million. It is important to figure out how to pay for the innovation which is quite challenging.

The pricing and paying for getting the products to market are important challenges. The innovation may take several years from clinical trial phase to get launched in the market. The investors may be disappointed if the company doesnt show expected profits and loses the hope while stock prices fall. This means that companies must carefully manage expectations and maintain balance.

It includes highlights of reports published in 2019 on the following biotech markets:

Covid 19 Impact[emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/12599

Go here to see the original:
Biotechnology Research Market 2023: Potential growth, attractive valuation make it is a long-term investment - Scientect

Puma Biotechnology, Inc. (NASDAQ:PBYI) went up by 8.00% from its latest closing price compared to the recent 1-year high of $15.00. The companys stock price has collected 6.54% of gains in the last five trading sessions. Press Release reported on 09/08/20 that Puma Biotechnology to Present at the H.C. Wainwright 22(nd) Annual Global Investment Conference

Plus, the 36-month beta value for PBYI is at 1.17. Opinions of the stock are interesting as 1 analysts out of 11 who provided ratings for Puma Biotechnology, Inc. declared the stock was a buy, while 0 rated the stock as overweight, 6 rated it as hold, and 3 as sell.

The average price from analysts is $11.67, which is $1.41 above the current price. PBYI currently public float of 34.31M and currently shorts hold a 21.70% ratio of that float. Today, the average trading volume of PBYI was 894.18K shares.

PBYI stocks went up by 6.54% for the week, with a monthly jump of 3.53% and a quarterly performance of 7.43%, while its annual performance rate touched -9.20%. The volatility ratio for the week stands at 5.27% while the volatility levels for the past 30 days are set at 5.67% for Puma Biotechnology, Inc.. The simple moving average for the period of the last 20 days is 1.00% for PBYI stocks with a simple moving average of 3.19% for the last 200 days.

Many brokerage firms have already submitted their reports for PBYI stocks, with BofA/Merrill repeating the rating for PBYI by listing it as a Underperform. The predicted price for PBYI in the upcoming period, according to BofA/Merrill is $9 based on the research report published on June 25th of the current year 2020.

Goldman, on the other hand, stated in their research note that they expect to see PBYI reach a price target of $8, previously predicting the value of $24. The rating they have provided for PBYI stocks is Sell according to the report published on October 8th, 2019.

Citigroup gave a rating of Neutral to PBYI, setting the target price at $24 in the report published on May 10th of the previous year.

After a stumble in the market that brought PBYI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.60% of loss for the given period.

Volatility was left at 5.67%, however, over the last 30 days, the volatility rate increased by 5.27%, as shares surge +4.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.56% lower at present.

During the last 5 trading sessions, PBYI rose by +6.54%, which changed the moving average for the period of 200-days by +9.73% in comparison to the 20-day moving average, which settled at $10.18. In addition, Puma Biotechnology, Inc. saw 17.26% in overturn over a single year, with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at PBYI starting from BRYCE RICHARD PAUL, who sold 90 shares at the price of $9.77 back on Sep 02. After this action, BRYCE RICHARD PAUL now owns 76,907 shares of Puma Biotechnology, Inc., valued at $879 using the latest closing price.

AUERBACH ALAN H, the PRESIDENT AND CEO of Puma Biotechnology, Inc., sold 347 shares at $9.78 during a trade that took place back on Sep 02, which means that AUERBACH ALAN H is holding 4,303,569 shares at $3,393 based on the most recent closing price.

Current profitability levels for the company are sitting at:

The net margin for Puma Biotechnology, Inc. stands at -27.77. The total capital return value is set at -24.14, while invested capital returns managed to touch -47.06. Equity return is now at value -246.90, with -17.40 for asset returns.

Based on Puma Biotechnology, Inc. (PBYI), the companys capital structure generated 688.48 points at debt to equity in total, while total debt to capital is 87.32. Total debt to assets is 51.18, with long-term debt to equity ratio resting at -2.60. Finally, the long-term debt to capital ratio is 673.45.

When we switch over and look at the enterprise to sales, we see a ratio of 1.24, with the companys debt to enterprise value settled at 0.35. The receivables turnover for the company is 10.71 and the total asset turnover is 1.10. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.83.

Read more here:
Is a Correction Looming Ahead for Puma Biotechnology, Inc. (PBYI) - The News Heater

Despite their ability to create matter out of thin air, algae and cyanobacteria have long been neglected by the biotech industry. Recently, however, they have started to gain traction in new market niches.

In the center of Paris, just across from Marie Curies old laboratory, Pierre Crozet, Associate Professor at Sorbonne University, studies photosynthesis. His research focuses on making microalgae easier to engineer and thus more appealing to the industry. [Microalgae] are photosynthetic, and quite efficient at it, but require much less space or nutrients than land plants, he told me.

The idea that new technologies should serve sustainability has started taking root in society. Using photosynthetic microbes for biotech applications appears to be a no-brainer. Algae grow biomass literally out of thin air, only needing water, carbon dioxide, and inorganic nutrients. Many grow on seawater and in lands not suitable for agriculture.

Today, we are managing quite well in transforming algae. I would thus not consider it particularly difficult, says Crozet, pointing out that, nowadays, obtaining a new strain of algae using genetic engineering takes just weeks. So, technically, they should be able to effectively replace bacteria and yeast, which generally require more complex growth facilities as well as the input of a sugar source in order to be able to generate any product.

However, algae have historically not been considered a good alternative to yeast and bacteria because of their slower growth rate. In addition, the crash of many algae biofuel companies about a decade ago dealt a blow to the field that it still has trouble recovering from.

The early 2010s saw several startups forming to produce biofuels, mainly in the US. Many claimed to be close to offering algal biofuel at competitive market prices. Sapphire Energy, Solazyme, and Algenol, among others, received significant public and private investments and built up high expectations. But due to technological challenges and the drop in oil prices between 2015 and 2016, no product became commercially viable and these businesses either went bankrupt or had to radically change their focus.

The [challenge] of algae and cyanobacteria comes down to their slow growth and the cost of production, says Hugh Goold, Research Scientist at the NSW Department of Primary Industries, Australia. According to Goold, the resources required to keep photosynthesis going is very high, meaning they dont replicate as quickly as the bacteria and yeast commonly used in biotech applications.

Bacteria and yeast have been optimized for many years in biotech applications such as producing commodity chemicals as well as high-value compounds such as pharmaceuticals, meaning that photosynthetic organisms can no longer compete with these applications. Investors have to know that you are going to produce a product cheaper than other people can. It isnt worthwhile to produce something in algae instead of E. coli just because, said Goold.

Despite this challenge, algae and cyanobacteria have started to get interest from new market niches where they could offer key advantages over traditional bioproduction methods.

Microalgae capture sunlight using pigments of vibrant colors, such as chlorophylls, carotenoids, and phycocyanin. In particular, the algae spirulina and chlorella found their way to the market a long time ago as food supplements and food colorants. Algae are also an excellent source of protein, which opens up a lot of opportunities in the production of meat analogs and vegan food in general.

Unilever, a massive producer of food and other consumer goods, has seen the nutritional potential of microalgae, partnering with UK-based company Algenuity in July. Algae are a source of high-quality plant-based protein, said Manfred Aben, Vice President of Science & Technology at Unilever. These products will appeal to a variety of consumers; for vegans and vegetarians but also for flexitarians and meat-eaters looking to reduce their consumption of animal products.

Within the food and beverage sector, the opportunities for microalgae-based ingredients are strong and tangible, explained Andrew Spicer, CEO of Algenuity. We do anticipate applications for microalgae-based ingredients in markets other than food and beverages where similar drivers around sustainability, plant-based, and natural sources of ingredients are equally strong.

Last year, the Dutch food and biochemical company Corbion announced a similar partnership with Nestl, signaling that big players in the food industry are starting to increasingly recognize the potential value of algae products. Other companies gaining traction in the field are Algama in France seeking to provide meat alternatives, and AlgaEnergy in Spain producing food and feed as well as cosmetics and fertilizers from algae.

In 2011, Renana Krebs graduated from the Shenkar College of Engineering, Design, and Art in Tel Aviv with a degree in fashion. While working for fashion brands, she realized the huge impact the industry has on the environment. Clothes and textiles manufacturing accounts for 10% of global carbon emissions and 20% of wastewater. Looking for alternative solutions, Krebs teamed up with her father and founded Algalife, a German-Israeli company offering algae-based fibers and textiles.

Algalife stands for a better planet and a better fashion industry. We provide and enable the opportunity for everyone to make better choices, for a healthy, sustainable well-being, Krebs told me. The company collaborates with fashion brands that are willing to learn and adjust their practices to include the green fibers, and even pay more for sustainable solutions.

Renana Krebs considers algae as one of the most influential resources for sustainable development, and notes that she gets requests from companies outside the fashion industry.

Over in San Diego, California, the startup Algenesis has been using algae oil as a replacement for petroleum. The two first products launched by the startup, whose founders are all surfers, are a surfboard and flip flops made from an algal biopolymer that is biodegradable.

In addition to fashion, algae can also be used to produce sustainable alternatives to everyday petrochemical products. For example, the startup Living Ink, in the US, aims to provide an eco-friendly alternative to printing ink using cyanobacteria.

After some initial hiccups, algae seem to be finding their way into the market. The new generation of startups in this field focus more on business-to-business relationships but build their branding around customers demand for environmentally friendly products.

It seems clear that cyanobacteria and algae will not replace bacteria and yeast as fermentation organisms in traditional applications. However, they have unique characteristics and a potential waiting to be unlocked by more research and daring business ideas. I cannot see limitations to what can be done with algae, but our own imagination, noted Crozet.

Cover illustration by Elena Resko, pictures courtesy of AlgaEnergy and AlgaLife

Go here to see the original:
After Years of Neglect, Algae Biotechnology Makes a... - Labiotech.eu

Global Food Biotechnology Industry 2020 Market Research Reportis an in depth study providing complete analysis of the Food Biotechnology Market for the period 20202025. It provides complete overview of market size, share, growth, trends, industry chain structure, top manufacturers Food Biotechnology market dynamics and competitive scenario.

Get Sample Copy athttps://www.orianresearch.com/request-sample/1515419

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.

Development policies and plansare discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin by regions North America, Europe, Japan, China, and other regions (India, Southeast Asia, Central & South America, and Middle East & Africa) and other regions can be added.

GlobalFood Biotechnology Marketreport has been compiled through extensive primary research (through analytical research, market survey and observations) and secondary research. The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

Key Companies Analyzed in this Report are:

ABS Global

Arcadia Biosciences

AquaBounty Technologies

BASF Plant Science

Bayer CropScience AG

Camson Bio Technologies Ltd

Dow AgroSciences LLC

DuPont Pioneer

Evogene Ltd

Hy-Line International

KWS Group

Monsanto

Origin Agritech Limited

Syngenta AG

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Animals

Plants

Others

Place a Direct Order Of this Report @https://www.orianresearch.com/checkout/1515419

Major Points Covered in Table of Contents:1 Industry Overview

2 Industry Environment (PEST Analysis)

3 Food Biotechnology Market by Type

4 Major Companies List

5 Market Competition

6 Demand by End Market

7 Region Operation

8 Marketing & Price

9 Research Conclusion

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on The World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (832) 380-8827 | UK: +44 0161-818-8027

Email:[emailprotected]

Continue reading here:
Food Biotechnology Industry Growth, Regional Trends, Top Manufacturers, Share and 2020-2025 Forecast - The News Brok

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Quarter Results/Quarterly / Interim StatementB.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN is pleased with its results for the first nine months of the 2019/20 financial year

31.08.2020 / 08:30 The issuer is solely responsible for the content of this announcement.

BRAIN is pleased with its results for the first nine months of the 2019/20 financial year

Zwingenberg, Germany31 August 2020

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG, ISIN DE0005203947 / WKN 520394) today published its results for the first nine months of the 2019/20 financial year. Accordingly, the BRAIN Group reports revenues of ? 29.6 million compared to ? 27.9 million in the same period of the previous year. Taking into account the deconsolidation of Monteil Cosmetics GmbH, this corresponds to organic growth of 12.2%.

Third quarter revenues increased by 8.4% to ? 9.6 million from ? 8.9 million in the same period last year. This growth was purely organic, achieved in both the BioScience and BioIndustrial segments.

"Particularly considering the general economic situation, we have achieved very good growth," says Manfred Bender, CFO of BRAIN AG. "The fact that this growth is more pronounced in our research-driven segment is again due to the higher business volume with existing customers as well as new contracts for tailormade solutions projects."

Development by segments

The BioScience segment generated revenues of ? 10.5 million in the reporting period, up 37.5% from the prior-year period. Adjusted EBITDA improved from ? -4.4 million to ? -3.1 million.

Revenues of the BioIndustrial segment, which is related to product sales, decreased by 5.9% from ? 20.3 million to ? 19.1 million in the reporting period. Organically, revenues here increased by ? 0.4 million or 2.1% from ? 18.7 million to ? 19.1 million. The adjusted EBITDA of the segment developed positively and increased by 9.2% from ? 2.3 million to ? 2.6 million. This corresponds to an adjusted EBITDA margin of 13.3% compared to 11.5% in the previous year.

The reasons for the weaker revenue growth in the product business are, in addition to the start of new production facilities in Cardiff (UK) and Bttelborn, the globally reduced demand for bioethanol and alcoholic beverages due to the Corona pandemic. The BRAIN subsidiary WeissBioTech supplies, among others, powerful enzymes to bioethanol producers and the wine industry.

Despite the ongoing Corona virus pandemic and the associated economic uncertainty, BRAIN AG is still confident to make further progress in the projected direction, albeit possibly at a slightly slower pace.

Key financials (first nine months of fiscal year 2019/20)

More detailed information on the financial results are available at http://www.brain-biotech.com/investors/financial-publications as part of the quarterly statement for the period ended 30 June 2020.

Financial Calendar:

http://www.brain-biotech.com/investors/financial-calendar

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of the bioeconomy. As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by means of "Nature's Toolbox" are successfully applied in the chemicals, cosmetics and food industries.

BRAIN's business model is based on two pillars. The BioScience segment mainly comprises research and development business with industrial partners ("Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of business with industrially scalable products.

B.R.A.I.N.Biotechnology ResearchAnd Information Network AGDarmstdter Str. 34-3664673 ZwingenbergGermanywww.brain-biotech.com

Contact Investor RelationsMichael SchneidersPhone: +49-6251-9331-86Email: mis@brain-biotech.com

Contact MediaDr. Stephanie KonlePhone: +49-(0)-6251-9331-70Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)

31.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Continue reading here:
BRAIN Biotechnology Research And Information Network AG: BRAIN is pleased with its results for the first nine months of the 2019/20 financial year -...

The 39 rating InvestorsObserver gives to Menlo Therapeutics Inc (MNLO) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 29 percent of stocks in the Biotechnology industry, MNLOs 39 overall rating means the stock scores better than 39 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 39 would rank higher than 39 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Menlo Therapeutics Inc (MNLO) stock has risen 4.73% while the S&P 500 is lower by -0.03% as of 3:12 PM on Monday, Aug 31. MNLO is up $0.07 from the previous closing price of $1.48 on volume of 1,790,999 shares. Over the past year the S&P 500 has gained 20.67% while MNLO is lower by -67.98%. MNLO lost -$3.75 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Menlo Therapeutics Inc click here.

Read more from the original source:
Is Menlo Therapeutics Inc (MNLO) a Winner in the Biotechnology Industry? - InvestorsObserver

Iovance Biotherapeutics Inc (IOVA) is near the middle in its industry group according to InvestorsObserver. IOVA gets an overall rating of 51. That means it scores higher than 51 percent of stocks. Iovance Biotherapeutics Inc gets a 53 rank in the Biotechnology industry. Biotechnology is number 23 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Iovance Biotherapeutics Inc (IOVA) stock is higher by 4.39% while the S&P 500 has fallen -0.08% as of 11:20 AM on Monday, Aug 31. IOVA has risen $1.39 from the previous closing price of $31.68 on volume of 584,032 shares. Over the past year the S&P 500 is up 20.60% while IOVA has risen 63.15%. IOVA lost -$1.93 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Iovance Biotherapeutics Inc click here.

More:
Is Iovance Biotherapeutics Inc (IOVA) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The 63 rating InvestorsObserver gives to Heat Biologics Inc (HTBX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, HTBXs 63 overall rating means the stock scores better than 63 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Heat Biologics Inc (HTBX) stock is trading at $1.26 as of 9:52 AM on Monday, Aug 31, a decline of -$0.08, or -5.97% from the previous closing price of $1.34. The stock has traded between $1.25 and $1.36 so far today. Volume today is below average. So far 1,467,087 shares have traded compared to average volume of 35,406,604 shares.

To see InvestorsObserver's Sentiment Score for Heat Biologics Inc click here.

Read the original here:
Is Heat Biologics Inc (HTBX) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver